Sunday, November 15, 2026

Peer-Reviewed Clinical Evidence Platform

The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 18 briefings matching “cholesterol”

Reset all filters

Filtered Archive

Matching Peer-Reviewed Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

CARDIOLOGY · REAL-WORLD COHORT

Full-Fat Dairy: Reassessing Decades of Dietary Advice

Full-fat dairy may not be the metabolic villain once thought, prompting a review of dietary advice. These findings suggest current dietary guidelines regarding dairy consumption may need re-evaluation, potentially impacting patient counseling.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 12, 2026

CARDIOLOGY · CLINICAL PRACTICE

Senior Statins: Short-Term Safety, Long-Term Questions

While stopping statins after 70 might initially seem safe for those without prior heart events, the long-term risks suggest a careful discussion with your doctor is essential. For years, the medical community has debated the optimal duration of statin therapy, especially as patients enter advanced age.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 13, 2026

ONCOLOGY · PRECLINICAL

Fructose Uncovered as a Driver of Ovarian Cancer Metastasis Post-Chemotherapy

Fructose metabolism, particularly post-chemotherapy, may represent a novel and actionable therapeutic target to impede ovarian cancer metastasis. Ovarian cancer often presents at an advanced stage, and despite initial responses to chemotherapy, recurrence and metastasis remain the primary causes of morbidity and risk of death.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readScienceDailyNov 12, 2026

CARDIOLOGY · PHASE III

Coronary Artery Calcium Scoring Challenges Traditional Statin Prescription Guidelines

Coronary Artery Calcium (CAC) guided statin initiation resulted in similar major cardiovascular event rates with fewer prescriptions and significantly improved patient adherence compared to traditional risk assessments. Current standard of care for primary prevention statin initiation heavily relies on calculated risk scores (e.g., ASCVD risk in the US), which estimate the 10-year risk of atherosclerotic cardiovascular disease events based on factors like age, sex, race, cholesterol levels, blood pressure, and diabetes status.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readScienceDailyNov 12, 2026

CARDIOLOGY · REAL-WORLD COHORT

Gene Editing: Lifelong Promise, Long-Term Safety Question

While gene editing offers the potential for lifelong disease prevention, its permanent effects demand rigorous, extended safety validation before widespread clinical use. If successful, this could significantly improve patient adherence and outcomes for chronic conditions by eliminating the need for daily medication.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 12, 2026

NEUROLOGY · PRECLINICAL

Liver Rejuvenation Halves Alzheimer's Protein, Lowers Cholesterol in Rats

Rejuvenating the liver with novel therapies could unexpectedly offer protection against both Alzheimer's disease and heart disease. This surprising discovery suggests that targeting liver health could offer a novel therapeutic strategy for preventing or treating both Alzheimer's disease and cardiovascular disease.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readScienceDailyNov 12, 2026

CARDIOLOGY · PRECLINICAL

Hidden Pathway in Cholesterol Regulation Identified, Novel Drug Shows Promise

A newly identified cholesterol regulation pathway and a drug in early development targeting it hold promise for future high LDL-C treatments. This discovery offers a novel therapeutic target for managing high cholesterol, potentially benefiting patients whose LDL levels are not adequately controlled by current treatments.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readScienceDailyNov 12, 2026

CARDIOLOGY · PHASE I/II

Novel Mechanism for High Cholesterol Uncovered, New Drug Pathway Promising

Targeting a novel pathway that disrupts natural cholesterol regulation could soon provide a powerful new strategy for managing high LDL cholesterol. This breakthrough offers a potential new therapeutic avenue for individuals with high cholesterol, especially those who may not respond optimally to current treatments.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readScienceDailyNov 12, 2026

CARDIOLOGY · REAL-WORLD COHORT

Inflammation and early atherosclerosis beyond traditional risk factors: an imaging study

Inflammation contributes to SA burden, as assessed by direct plaque quantification, beyond the effects of LDLc and SBP. These findings indicate that inflammation, captured through the use of systemic inflammatory markers, is a risk factor relevant across the entire continuum of atherosclerosis, exerting a deleterious impact comparable to that of LDLc and SBP.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readEuropean Heart JournalNov 10, 2026

CARDIOLOGY · REAL-WORLD COHORT

AI-Identified Reasons for Nonescalation of Lipid-Lowering Therapy for Secondary Prevention

Results of this study show that after using a state-of-the art LLM, nearly 9 in 10 ASCVD encounters with above-goal LDL-C level did not have patient LLT escalated, most often because of adverse effects, patient preference, preference for lifestyle changes, therapeutic inertia (eg, repeat laboratory tests), and near-goal LDL-C level. These findings highlight an avenue for personalizing system-level digital health interventions to help discover and minimize guideline-discordant care gaps in secondary prevention of ASCVD.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readJAMA CardiologyNov 7, 2026

CARDIOLOGY · RANDOMIZED CLINICAL TRIAL

Statin-Ezetimibe Combination Therapy versus Statin Monotherapy in Atherosclerotic Cardiovascular Disease: A Prespecified Secondary Analysis of the Randomized Ez-PAVE Trial

Within a target-directed LDL-C-lowering strategy, cardiovascular efficacy (real-world effectiveness in the trial) and safety did not differ significantly, whether initiated as statin-ezetimibe combination therapy or as statin monotherapy, but combination therapy facilitated achievement of a lower LDL-C target. In a target-directed low-density lipoprotein cholesterol (LDL-C)-lowering strategy, the impact of the initial treatment regimen has not been investigated in patients with atherosclerotic cardiovascular disease.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readCirculationNov 7, 2026

CARDIOLOGY · RANDOMIZED CLINICAL TRIAL

Intensive vs More Intensive Lipid-Lowering Therapy and Plaque Regression in Statin-Naive Patients: Prespecified Analyses From the FLOWPROMOTE Randomized Clinical Trial

This secondary analysis of the FLOWPROMOTE randomized clinical trial demonstrated that in statin-naive patients with CAD, more intensive lipid-lowering therapy was associated with significantly greater regression of total and noncalcified coronary plaque burden compared with intensive therapy. The extent of plaque regression was related to achieved LDL-C levels, supporting the potential for partial reversal of coronary atherosclerosis with intensive lipid reduction.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readJAMA CardiologyOct 30, 2026

Showing 12 of 18 medical briefings

Interactive Fact Check